Items Tagged ‘Recurrent Ovarian Cancer’

April 9th, 2014

Avastin Plus Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer

By

The addition of Avastin® (bevacizumab) to standard chemotherapy significantly improved progression-free survival and objective response rate among women with platinum-resistant recurrent ovarian cancer, according to the results of a study published early online in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer


February 20th, 2014

Aspirin as Ovarian Cancer Prevention? Research Says Maybe

By

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk of several serious health issues. Studies have also found that an […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Screening/Prevention Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


January 30th, 2014

Dacogen Helps Recurrent Ovarian Cancer Respond to Vaccine

By

Treatment with Dacogen® (decitabine) prior to the administration of Adriamycin® (doxorubicin) and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, according to a study published in Cancer Immunology Research. Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is the fifth leading cause of cancer death among U.S. women, […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


October 21st, 2013

Cediranib Improves Survival in Recurrent Ovarian Cancer

By

Women with recurrent ovarian cancer experienced significantly improved survival when they received targeted agent cediranib with chemotherapy and as maintenance therapy after chemotherapy, according to the results of a study presented at the ESMO 2013 Congress of the European Society for Medical Oncology in Amsterdam. Ovarian cancer has the highest mortality rate of all gynecologic […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer


May 17th, 2013

Novel Two-step Immunotherapy Shows Promise in Recurrent Ovarian Cancer

By

A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, according to data from two phase I clinical trials presented at the American Association for Cancer Research (AACR) Annual Meeting 2013, held in Washington, D.C., April 6-10.  Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer


February 7th, 2013

Ovarian Cancer Rates Declining in Breast Cancer Survivors

By

The rate of second primary ovarian cancers after first primary breast cancer appears to be on the decline, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Overall incidence […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Screening/Prevention Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


December 3rd, 2012

Diabetes Drug May Help Prevent or Treat Ovarian Cancer

By

Metformin, a widely prescribed insulin-lowering drug for diabetes, has been associated with survival in ovarian cancer and is worthy of further study, as it may be considered for the prevention or treatment of ovarian cancer, according to the results of a study published in Cancer.[1] Each year in the United States, roughly 22,000 women are diagnosed […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Screening/Prevention Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


November 20th, 2012

Treatment at High-Volume Hospitals Leads to Lower Mortality Rates for Ovarian Patients

By

Ovarian cancer patients who undergo surgery at high-volume hospitals have better outcomes than those who are treated at low-volume hospitals, according to the results of a study published in the Journal of Clinical Oncology. This is the result not of lower complication rates, but of a better response to complications. Each year in the United […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


September 28th, 2012

Gene Helps Predict Response to Chemotherapy in Ovarian Cancer

By

Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Journal of Cancer. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


August 10th, 2012

Olaparib Improves Progression-Free Survival in Ovarian Cancer

By

Olaparib plus paclitaxel and carboplatin chemotherapy followed by olaparib maintenance therapy improved progression-free survival compared to chemotherapy alone in platinum-sensitive ovarian cancer, according to the results of a study presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Ovarian cancer has the highest mortality rate of all […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer


June 8th, 2012

Avastin Plus Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Ovarian Cancer

By

The addition of Avastin® (bevacizumab) to standard chemotherapy doubled progression-free survival (PFS) in women with platinum-resistant ovarian cancer, according to the results of a study presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois Each year in the United States, roughly 22,000 women are diagnosed with ovarian […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer


April 3rd, 2012

Olaparib Delays Progression of Ovarian Cancer

By

In a phase II clinical trial, olaparib (a type of targeted therapy known as a PARP inhibitor) delayed cancer progression—but did not improve overall survival—when given after chemotherapy to women with relapsed, platinum-sensitive, serous ovarian cancer. These results were published in the New England Journal of Medicine. Ovarian cancer has the highest mortality rate of […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer


June 6th, 2011

Avastin Shows Benefit in Ovarian Cancer

By

The addition of the targeted drug Avastin® (bevacizumab) to chemotherapy may improve outcomes among women with newly diagnosed or recurrent ovarian cancer. These results—from two Phase III clinical trials—were presented at the 2011 annual meeting of the American Society of Clinical Oncology. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Outcomes for women diagnosed […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


May 31st, 2011

Cabozantinib Shows Promise against Bone Metastases

By

The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual meeting of the American Society of Clinical Oncology. Metastatic cancer refers to cancer that has […]

View full entry

Tags: Breast Cancer, Liver Cancer, Melanoma, Metastatic Breast Cancer, News, Ovarian Cancer, Prostate Cancer, Recurrent Breast Cancer, Recurrent Liver Cancer, Recurrent Melanoma, Recurrent Ovarian Cancer, Refactory/Recurrent Prostate Cancer


May 27th, 2011

PARP Inhibitor Delays Progression of Ovarian Cancer

By

In a phase II clinical trial, olaparib (a type of targeted therapy known as a PARP inhibitor) delayed cancer progression when given after chemotherapy to women with relapsed, platinum-sensitive, serous ovarian cancer. These results will be presented at the 2011 annual meeting of the American Society of Clinical Oncology. Ovarian cancer has the highest mortality […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer